BHCM
ELVN icon

Brevan Howard Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Brevan Howard Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66M Buy
32,718
+10,486
+47% +$445K 0.01% 808
2026
Q1 		$871K Buy
+22,232
New +$616K 0.01% 979
2025
Q1 		– Sell
-10,144
Closed -$228K – 1244
2024
Q4 		$228K Buy
+10,144
New +$263K ﹤0.01% 870

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Brevan Howard Capital Management's ELVN Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Enliven Therapeutics (ELVN) stake by 47% in Q2 2026, buying an estimated $445K and bringing the position to 32,718 shares worth $1.66M. The position accounts for 0.01% of the portfolio, ranked #808.

Brevan Howard Capital Management first reported a position in ELVN in Q4 2024 and has held it in 3 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Brevan Howard Capital Management held 32,718 shares of Enliven Therapeutics worth $1.66M as of Q2 2026.
  • Brevan Howard Capital Management bought 10,486 Enliven Therapeutics shares in Q2 2026, an estimated $445K.
  • Enliven Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #808 holding.
  • Brevan Howard Capital Management first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.